Conexeu Sciences puts the aesthetics opportunity it is chasing at roughly $2 billion by 2030, and its first anticipated regulatory filing is still months away. The Nasdaq-listed company (CNXU) has just opened a new research and development lab in Vancouver to work toward it.
The lab sits inside adMare BioInnovations’ M4 Innovation Centre, a 30,000-square-foot hub for life sciences firms that offers specialized laboratory space and shared scientific resources. Conexeu cut the ribbon on June 23, 2026, and says it is among the first companies to operate there. The announcement was issued on the company’s behalf.
Conexeu calls itself a preclinical-stage company. Nothing it makes has been cleared or approved.
The product
The lab will anchor work on CXU, a patented extracellular matrix platform that the company describes as one formula and one device meant to serve several markets. Its lead candidate, Ten-Minute Tissue, stays liquid at room temperature and is designed to turn into a stable gel at body temperature in about ten minutes. It is a bioresorbable scaffold intended to help the body rebuild its own soft tissue.
The company says it has spent more than a decade studying how the material behaves in living tissue, and points to eleven peer-reviewed publications showing that the body accepted the material and that its own cells moved in and multiplied. Patents are issued in the U.S., the E.U., Japan and Australia, with one pending in Canada. Conexeu says it holds all rights to the platform with no royalty or licensing obligations.
The lab will also handle B.R.E.A.S.T., a 3D-bioprinted breast matrix intended to help the body regenerate natural tissue after mastectomy.
Why aesthetics, and why now
The pitch ties back to weight-loss drugs. GLP-1 therapies have shrunk millions of waistlines, and the company says they also cause facial and body volume loss that current tools were not built to treat. It cites Boston Consulting Group projecting that provider revenue from GLP-1-related concerns will grow from $700 million to $2 billion over five years. Morgan Stanley Research, in an April 2026 note, expects the GLP-1 drug market itself to reach about $190 billion by 2035, up from roughly $79 billion in sales in 2025.
“This facility represents an important achievement for Conexeu and our mission to advance breakthrough regenerative tissue technologies towards aesthetics,” said Dr. Claudia Chavez-Munoz, co-founder and chief scientific officer.
The regulatory plan is predicate-based. Conexeu anticipates a 510(k) submission in early 2027, subject to FDA review, and the company says the same platform extends to wound care and periodontal uses. It lists AbbVie, Eli Lilly, Galderma and Establishment Labs as active players in the broader field, while stressing that none is a comparable and that it has no partnership with any of them.
The company’s own materials state that the safety and effectiveness of its device candidates have not been established by the FDA.
